Asthma Flashcards

1
Q

epidemiology in US

A

-Affects 8–10% of the population
-Annual Data:
-10 million office visits
-1.8 million ED visits
-> 3500 deaths

-Slightly more common in boys (< 14 years old) and in women
-One MC chronic diseases worldwide
-~300 million affected individuals
-Prevalence increasing in many countries, especially in children
-A major cause of school/work absence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

asthma is increasing every year in the US

A

-In 2016: adults and children with asthma was 26.5 million
-Since 2001, asthma prevalence increased at a rate of 1.5% each year, to 8.3% in 2016
-As of 2016, the average asthma prevalence was:
-Highest in children 12-14 years old
-Higher in women than men
-Higher in blacks than whites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

burden

A

-A high economic and personal burden exists for people with asthma
-During 2008-2013, asthma was responsible for $3 billion in losses due to missed work and school days, $29 billion due to asthma-related mortality, and $50.3 billion in medical costs.
-Between 2008-2013, asthma resulted in an estimated loss of 1.8 days from work each year, and 2.3 days from school each year, per person

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

asthma

A

-chronic inflammatory disorder of airways
-Chronic inflammation causes associated airflow obstruction (bronchoconstriction, airway hyperresponsiveness and airway edema)
-Symptoms: recurrent coughing, wheezing, breathlessness and chest tightness
-Involves widespread, variable airflow limitation (often reversible, either spontaneously or with treatment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

pathophysiology

A

-Chronic inflammatory disorder of airways:
-Hypertrophy of bronchial smooth muscle and mucous glands
-Plugging of small airways with thick mucous

-Airway inflammation-> ds chronicity -> airway hyper-responsiveness, airflow limitation, and respiratory symptoms
-allergic inflammation, eosinophilic inflammation, mucus overproduction -> narrowing -> many different places to intervene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

risk factors for development of asthma

A

-Genetic characteristics
-Environmental exposures
-Contributing factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

genetic characteristics

A

-Atopy:
-Predisposition to develop IgE in response to environmental allergens
-High IgE: more likely to have allergic response

-2-3x risk if have parent with asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

asthma triggers

A

-A definitive cause of the inflammatory process leading to asthma has not yet been established
-Several factors, including both genetic and environmental, are thought to play a role in asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

non-atopic vs atopic

A

-non-atopic:
-Ozone
-Smoke
-Particulate matter
-Infection
-Some medications(aspirin, beta blockers, ACE inhibitors)
-Cold, dry air

-atopic:
-House dust mite
-Pollen
-Ragweed
-Cockroach
-Mold
-Pet dander/saliva
-Foods (peanuts, soy, shellfish, milk)
-Natural oils and fragrances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

allergic and nonallergic phenotypes

A

-most commonly discussed phenotypes of asthma -> allergic and nonallergic
-many pts with asthma display characteristics of both phenotypes, including an increase in type 2 inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

allergic (atopic or extrinsic)

A

-triggers- allergic rxn to inhaled allergens (dust mite allergen, pet dander, pollen and mold
-age at development- usually begins in childhood
-symptoms- many similarities with non allergic -> coughing, wheezing, SOB, hyperventilation, chest tightness
-inflammatory process- can be similar to nonallergic -> increased TH2 cells, mast cell activation and infiltration of eosinophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

nonallergic (nonatopic or intrinsic)

A

-triggers- factors not related to allergies (anxiety, stress, exercise, cold or dry air, hyperventilation, tobacco smoke, viruses or other irritants)
-age at development- tends to develop in adults (>35 years of age)
-symptoms- many similarities with non allergic -> coughing, wheezing, SOB, hyperventilation, chest tightness
-inflammatory process- can be similar to nonallergic -> increased TH2 cells, mast cell activation and infiltration of eosinophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

diagnosing asthma: medical hx

A

-Symptoms
-Patterns to Symptoms (freq at night, seasonal)
-Severity (impact on life)
-Past Medical History
-Family History

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

diagnosing asthma: physical exam

A

-Wheezing
-Hyper-expansion of the thorax
-Increased nasal secretions or nasal polyps (sign of type 2 inflammation)
-Atopic dermatitis (sign of type 2 inflammation) or other allergic skin conditions
-During severe asthma exacerbations, airflow may be too limited to produce wheezing -> only dx clue on auscultation may be globally reduced breath sounds with prolonged expiration
-ABG changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

diagnosing asthma: spirometry

A

-Testing of lung function
-Determines presence and extent of airflow obstruction & if reversible
-Airflow obstruction- Reduced FEV1/FVC ratio (< 90% pred)
-Reversibility- Increase of ≥ 12% and 200 ml in FEV1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

flow volume loops: obstructive vs restrictive

A

-obstructive:
-loop shifts left -> volumes are > than normal
-FEV1 decreases more than FVC (lower FEV1/FVC

-restrictive:
-loops shifts to right
-volumes are < normal
-FEV1 and FVC decrease in proportion (normal or even elevated FEV1/FVC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

imaging studies

A

-Chest radiographs:
-Often normal
-Hyperinflation common (if active disease)
-may have bronchial wall thickening (edema and muscle wall hypertrophy)
-Useful in ruling out other conditions:
-Pneumonia, CHF or complications of asthma (pneumothorax)

18
Q

assessing asthma control and adjusting therapy NAEPP EPR-3: pts >= 12 years of age

A

-OCS- oral corticosteroids- this is bad!

19
Q

asthma control test chart

A

-its really important you are asking the right questions….asthma is very under appreciated
-many people report being fine and doctors too -> but in reality they are not well controlled

20
Q

approach to asthma tx

A

-chronic inflammation -> airway hyperresponsiveness -> increase susceptibility to bronchoconstriction
-bronchodilation controlled by stimulation of the adrenergic pathway through beta 2 receptors on ASM
-bronchoconstriction is regulated by stimulation of the cholinergic pathway through M3 receptors on bronchial smooth muscle
-beta agonist + anti cholinergic = combats chronic inflammation -> blocks constriction and promotes dilation

21
Q

stepwise approach for managing asthma

A

-step 1- SABA prn (bronchodilator)
-step 2- low dose inhaled corticosteroid (ICS)
-step 3- low dose ICD+ LABA OR medium dose ICS
-step 4- medium dose ICS + LABA (long acting beta agonist)
-step 5- high dose ICS + LABA AND consider omalizumab for pts who have allergies
-step 6- high dose ICS + LABA + oral corticosteroid AND consider omalizumab for pts who have allergies or other biologics
-step 4-5- specialized
-step up if needed and step down if possible (well controlled for at least 3 months)
-steps 2-4 consider subcutaneous allergen immunotherapy for pts who have allergic asthma
-when nothings working -> think about biologics

22
Q

inhaled medications

A

-Inhaled Medications are Topical Medications, not Systemic
-They only work if the medication gets to the targeted tissue
-Delivery system/Inhaler Choice and inhaler technique are very important.
-It is very important to demonstrate the inhaler technique and assess patient’s ability to use it properly

23
Q

medications to tx asthma: how to use a spray inhaler

A

-health care provider should evaluate inhaler technique at each visit
-stand up, breathe out
-as you start to breathe in -> push down on top of inhaler -> keep breathing in slowly
-hold your breathe for 10s
-breath out

-pMDI- hardest to use

-first thing you do when pt is being txed and are uncontrolled -> ask them to use inhaler in front of you -> if they are doing it perfectly….then consider stepping up

24
Q

meds to treat asthma: inhalers and spacers

A

-used for inhalers
-prevent dose from getting on back of throat or tongue
-maximizes dose

25
Q

dry powder inhaler

A

-need to generate more negative expiratory force for this
-not an issue for asthma but for COPD it can be

26
Q

nebulizers

A

-Uses compressed air machine to deliver medicine as a mist
-Good for small children, elderly, AMS, limited negative expiratory force, or for severe asthma episodes
-Short and long acting beta agonist and Inhaled Steroids available in nebulized form

27
Q

asthma meds categories

A

-Liquids, pills, powders, vapors, and injections
-2 major categories of medications are:
-Long-term control (inflammation)- maintenance, must take consistently, feel no difference but works over time -> educate your pt
-Quick relief (bronchoconstriction)
-a lot of pts are on long term and short term for episodes -> they neglect long term bc the short term makes them feel better

28
Q

quick relief

A

-used in acute asthma episodes
-generally they are short acting beta 2 agonists
-albuteral
-albuterol with ipatropium nebulizer

29
Q

long term control

A

-Taken daily
-Used to reduce inflammation, relax airway muscles, and improve symptoms and pulmonary function
Inhaled corticosteroids
-Long-acting beta2-agonists and anticholinergics/muscarinic antagonist
-Leukotriene modifiers
-Immune modulators and mast cell stabilizers
-inhaled steroids:
-fluticasone
-budesonide

30
Q

anticholinergic/muscarinic antagonist: tiotropium

A

-block bronchoconstriction
-long acting cholinergic
-LAMA- long acting muscarinic antagonist
-Approved by the FDA for long-term maintenance treatment in asthma
-An alternative to a long-acting beta agonist for patients over age 6

31
Q

leukotriene receptor antagonists (LTRAs)

A

montelukast

32
Q

immunomodulators (step 5)

A

-IgE Mediated Asthma- Omalizumab (Xolair)

-Eosinophilic Mediated Asthma (IL-5):
-Benralizumab (Fasenra)
-Mepolizumab (Nucala)
-Reslizumab (Cinqair)

-Mixed Eosinophilic and Allergic:
-Dupilumab (IL-4,13)
-Tezepelumab (TSLP)

-Methylxanthines- Theophylline

-biologics

33
Q

asthma management goals

A

-Control symptoms
-Prevent exacerbation
-Maintain lung function as close to normal as possible
-Avoid adverse effects from medications
-Prevent airway remodeling (irreversible airway obstruction)
-Prevent asthma mortality

34
Q

asthma management plan

A

-Tailor to meet individual needs
-Educate patients and families on all aspects of the plan:
-Recognizing symptoms
-Medication benefits and side effects
-Proper use of inhalers and peak expiratory flow (PEF) meters

35
Q

peak expiratory flow (PEF) meters

A

-A 20% change in PEF values from morning to afternoon or from day to day suggests inadequately controlled asthma.
-PEF values less than 200 L/min indicate severe airflow obstruction
-People with moderate or severe asthma should take readings:
-Every morning and evening
-After an exacerbation
-Before inhaling certain medications to monitor response
-check kids bc they cant verbalize

36
Q

approach to tx of mild asthma attack

A

-can be treated at home with quick-relief bronchodilator medication

37
Q

indications of a severe attack

A

-Breathless at rest
-Hunched forward
-Talking in words rather than sentences
-Agitated
-FEV1 or PEF< 40%

38
Q

severe exacerbation tx (inpatient)

A

-Receive oxygen
-High doses of an inhaled SABA with ipratropium q 20 min intervals or continuous for an hour
-Systemic corticosteroids

39
Q

vaccines

A

-Pneumococcal vaccine (Pneumovax)
-Annual influenza vaccinations

40
Q

summary

A

-Asthma is a chronic inflammatory disease characterized by reversible airflow obstruction
-Should be completely controllable/reversible. Shouldn’t need Rescue Inhaler more than once every 2 weeks
Stepwise management changes based on degree of control. Step up/Step down
-Asthma management plan includes education and frequent reassessment of ability to use inhalers and compliance with treatment.
-Maintenance therapies include ICS, LABA, LAMA, LTR and biologic therapies
-Minimize use of systemic steroids

41
Q

diffusing capacity

A

-asthma normal
-COPD low